Lymphoseek

Shares of Navidea Biopharmaceuticals Inc (NYSE: NAVB) surged higher by more than 25 percent on Friday after the company provided investors with a business update. Navidea said recent strategic changes to its corporate structure has given itself an "opportunity to refocus its efforts"...

On Tuesday, the FDA approved the second weight-loss drug in the last 13 years when it green-lighted Vivus' drug Qsymia. On Wednesday, VVUS shares have shot up more than 14 percent to $30.27. The approval of this drug and the excitement that it has created in the biotech investing community may...